SEC Comment Letter for BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) (BCRX) — May 17, 2017
BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)
Date: May 17, 2017 · CIK: 0000882796 · Accession: 0000000000-17-017399
AI Filing Summary & Sentiment
Reasoning
Letter
May 17, 2017 Jon P. Stonehouse President and Chief Executive Officer BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 BioCryst Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 10, 2017 File No. 333-217859Re: Dear Mr. Stonehouse: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare and Insurance cc: Robyn E. Zolman
Show Raw Text
May 17, 2017
Jon P. Stonehouse
President and Chief Executive Officer
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
BioCryst Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 10, 2017
File No. 333-217859Re:
Dear Mr. Stonehouse:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Division of Corporation Finance
Office of Healthcare and
Insurance
cc: Robyn E. Zolman